Lung cancer

[1]  Xue Wu,et al.  Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing , 2020, Molecular oncology.

[2]  Yanxi Han,et al.  Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[3]  Y. Shao,et al.  Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. , 2020, Pathology, research and practice.

[4]  Y. Miyagi,et al.  Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique , 2020, Thoracic cancer.

[5]  S. Murray,et al.  Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort , 2020, Journal for ImmunoTherapy of Cancer.

[6]  A. Stenzinger,et al.  Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.

[7]  M. Tiemann,et al.  TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC , 2020, Oncotarget.

[8]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[9]  Shi-yue Li,et al.  Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma , 2020, Orphanet Journal of Rare Diseases.

[10]  P. Guo,et al.  Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma , 2019, BMC Cancer.

[11]  F. Grossi,et al.  Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges , 2019, Cancers.

[12]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  Shuhang Wang,et al.  TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer , 2019, Cancer Immunology Research.

[14]  A. Drilon.  TRK inhibitors in TRK fusion-positive cancers. , 2019 .

[15]  K. Mertz,et al.  Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer , 2019, The Journal of pathology.

[16]  M. Catalán,et al.  Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions , 2019, Molecular oncology.

[17]  J. Lunceford,et al.  OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC , 2019, Journal of Thoracic Oncology.

[18]  J. Lunceford,et al.  OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC , 2019, Journal of Thoracic Oncology.

[19]  L. Bubendorf,et al.  TCR-beta repertoire convergence and evenness are associated with response to immune checkpoint inhibitors , 2019, Annals of Oncology.

[20]  R. Califano,et al.  Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions , 2019, OncoTargets and therapy.

[21]  J. Subramanian,et al.  Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice , 2019, Cancers.

[22]  David R. Jones,et al.  Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach , 2019, Clinical Cancer Research.

[23]  G. Burghel,et al.  The importance of neoplastic cell content assessment and enrichment by macrodissection in cancer pharmacogenetic testing , 2019, Journal of Clinical Pathology.

[24]  Minghui Wang,et al.  EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer , 2019, BMC Cancer.

[25]  Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center , 2019, Molecular Biology Reports.

[26]  Bin Xu,et al.  Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas , 2019, International Journal of Clinical Oncology.

[27]  Larissa V Furtado,et al.  Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis. , 2019, Archives of pathology & laboratory medicine.

[28]  J. Kashima,et al.  Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists , 2019, Cancers.

[29]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[30]  G. Otterson,et al.  Liquid biopsy for lung cancers: an update on recent developments. , 2019, Annals of translational medicine.

[31]  A. Addeo,et al.  Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? , 2019, Front. Oncol..

[32]  Jing Zhao,et al.  Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel , 2019, JAMA oncology.

[33]  S. Leroy,et al.  Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. , 2019, Journal of thoracic disease.

[34]  F. López-Ríos,et al.  Implementing TMB measurement in clinical practice: considerations on assay requirements , 2019, ESMO Open.

[35]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  T. Miyazaki,et al.  Brief Report: Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  F. Barlesi,et al.  The clinical utility of tumor mutational burden in non-small cell lung cancer. , 2018, Translational lung cancer research.

[38]  P. Hofman,et al.  Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? , 2018, Translational lung cancer research.

[39]  G. Lowman,et al.  TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[41]  N. Sunaga,et al.  Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer , 2018, Cancers.

[42]  Fiona Hyland,et al.  A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay. , 2018, Translational lung cancer research.

[43]  Joe Y. Chang,et al.  Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.

[44]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[45]  T. Qiu,et al.  Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. , 2018, Lung cancer.

[46]  Yibo Gao,et al.  Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. , 2018, Cancer letters.

[47]  P. Laurent-Puig,et al.  TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma , 2018, Clinical Cancer Research.

[48]  K. Reckamp.  Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[49]  G. Rossi,et al.  BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. , 2018, Cancer treatment reviews.

[50]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[51]  A. Shaw,et al.  Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.

[52]  Shujiro Okuda,et al.  Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung , 2018, Annals of Surgical Oncology.

[53]  Robyn L. Temple-Smolkin,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[54]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[56]  Radhe Mohan,et al.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Berger,et al.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[59]  M. Omata,et al.  Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. , 2017, European journal of cancer.

[60]  A. Shaw,et al.  Recent Advances in Targeting ROS1 in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  R. Bayliss,et al.  EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients , 2017, Cancers.

[62]  Joe Y. Chang,et al.  Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Final Results of a Phase 2 Study , 2017, JAMA oncology.

[63]  A. Bezjak,et al.  Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.

[64]  G. Troncone,et al.  How to prepare cytological samples for molecular testing , 2017, Journal of Clinical Pathology.

[65]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[66]  V. Miller,et al.  BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies. , 2017 .

[67]  R. Chiari,et al.  Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence , 2017, Medical Oncology.

[68]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[69]  Markus Alber,et al.  Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[70]  D. Gerber,et al.  ALK alterations and inhibition in lung cancer. , 2017, Seminars in cancer biology.

[71]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[72]  G. Fontanini,et al.  Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D , 2016, The Journal of pathology.

[73]  J. Minna,et al.  Molecular Basis of Lung Carcinogenesis , 2017 .

[74]  S. Ou,et al.  The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. , 2017, Lung cancer.

[75]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[76]  Di Yan,et al.  Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy. , 2016, International journal of radiation oncology, biology, physics.

[77]  Yufeng Shen,et al.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Marchetti,et al.  Review and Perspectives , 2022 .

[79]  T. Solberg,et al.  Technical Note: A treatment plan comparison between dynamic collimation and a fixed aperture during spot scanning proton therapy for brain treatment. , 2016, Medical physics.

[80]  Shinichi Shimizu,et al.  Optimization and evaluation of multiple gating beam delivery in a synchrotron-based proton beam scanning system using a real-time imaging technique. , 2016, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[81]  Ji-Ying Song,et al.  Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients , 2016, Cell reports.

[82]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[83]  J. Jen,et al.  Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases , 2016, Modern Pathology.

[84]  Zuofeng Li,et al.  A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. , 2016, International journal of radiation oncology, biology, physics.

[85]  Wei Liu,et al.  Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. , 2016, International journal of radiation oncology, biology, physics.

[86]  J. Davison,et al.  Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging , 2016, Modern Pathology.

[87]  Tatsuya Nakamura,et al.  Dosemetric Parameters Predictive of Rib Fractures after Proton Beam Therapy for Early-Stage Lung Cancer. , 2016, The Tohoku journal of experimental medicine.

[88]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  C. Moran,et al.  Primary Pulmonary Salivary Gland-type Tumors: A Review and Update , 2016, Advances in anatomic pathology.

[90]  Xiaodong Zhang,et al.  Reducing Dose Uncertainty for Spot-Scanning Proton Beam Therapy of Moving Tumors by Optimizing the Spot Delivery Sequence. , 2015, International journal of radiation oncology, biology, physics.

[91]  S. Dearden,et al.  Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review , 2015, Journal of experimental & clinical cancer research : CR.

[92]  A. Nicholson,et al.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[93]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[94]  G. Giaccone,et al.  Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  M. Mino‐Kenudson,et al.  Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[96]  Joe Y. Chang,et al.  Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[97]  V. Seshan,et al.  Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. , 2015, Cancer discovery.

[98]  Sheryl K Elkin,et al.  Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types , 2015, Cell cycle.

[99]  Y. Asmann,et al.  Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers , 2015, Scientific Reports.

[100]  P. Hammerman,et al.  Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics , 2015, Clinical Cancer Research.

[101]  N. Girard,et al.  High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  Holly Ning,et al.  Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. , 2015, Clinical lung cancer.

[103]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[104]  Baosheng Li,et al.  Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy. , 2015, Journal of cancer research and therapeutics.

[105]  Wei Liu,et al.  Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[106]  T. Akimoto,et al.  [Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction]. , 2015, Gan to kagaku ryoho. Cancer & chemotherapy.

[107]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[108]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[109]  W. D. Cress,et al.  Lung cancer mutations and use of targeted agents in Hispanics. , 2015, Reviews on recent clinical trials.

[110]  D. Gomez,et al.  Poster PresentationThe 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy: Locally Advanced Non-Small Cell Lung Cancer , 2014 .

[111]  Heng Li,et al.  Clinical implementation of intensity modulated proton therapy for thoracic malignancies. , 2014, International journal of radiation oncology, biology, physics.

[112]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[113]  M. Tsao,et al.  Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? , 2014, European Respiratory Journal.

[114]  K. Nishio,et al.  Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.

[115]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[116]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[117]  Ping Wang,et al.  Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. , 2014, The British journal of radiology.

[118]  H. Lee,et al.  Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation , 2014, Korean journal of pathology.

[119]  R. Shackelford,et al.  ALK-rearrangements and testing methods in non-small cell lung cancer: a review , 2014, Genes & cancer.

[120]  Joe Y. Chang,et al.  Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[121]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[122]  Y. Ichinose,et al.  The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. , 2013, Lung cancer.

[123]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[124]  J. Slater,et al.  High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. , 2013, International journal of radiation oncology, biology, physics.

[125]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.

[126]  Geoffrey D. Hugo,et al.  Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost. , 2013, International journal of radiation oncology, biology, physics.

[127]  Zuofeng Li,et al.  Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer , 2013, Acta oncologica.

[128]  L. Annemans,et al.  Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium? , 2013 .

[129]  Radhe Mohan,et al.  Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.

[130]  C. Ko,et al.  Feasibility of Proton Therapy for Elective Nodal Irradiation in Patients With Locally Advanced Non-small Cell Lung Cancer , 2012 .

[131]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[132]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[133]  U. Pastorino,et al.  Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. , 2012, Lung cancer.

[134]  T. Nagayasu,et al.  Clinical and molecular analysis of synchronous double lung cancers. , 2012, Lung cancer.

[135]  I. Umelo,et al.  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. , 2012, Lung cancer.

[136]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  Lei Dong,et al.  A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. , 2012, International journal of radiation oncology, biology, physics.

[138]  T. Hashimoto,et al.  Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[139]  Joe Y. Chang,et al.  Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer , 2011, Cancer.

[140]  K. Matsuo,et al.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  Joe Y. Chang,et al.  Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.

[142]  J. Aster,et al.  Differentiation of NUT midline carcinoma by epigenomic reprogramming. , 2011, Cancer research.

[143]  H. Dienemann,et al.  Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma , 2011, Journal of Clinical Pathology.

[144]  M. Tsao,et al.  EGFR mutations and lung cancer. , 2011, Annual review of pathology.

[145]  Akira Mogi,et al.  TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[146]  Joe Y. Chang,et al.  Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. , 2010, International journal of radiation oncology, biology, physics.

[147]  J. Slater,et al.  Comorbidity-Adjusted Survival in Early Stage Lung Cancer Patients Treated with Hypofractionated Proton Therapy , 2010, Journal of oncology.

[148]  Christoph Bert,et al.  Respiratory motion management in particle therapy. , 2010, Medical physics.

[149]  William Pao,et al.  Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases , 2009, The American journal of surgical pathology.

[150]  A. Italiano,et al.  EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti‐EGFR treatment of a rare lung malignancy , 2009, International journal of cancer.

[151]  T. Sakae,et al.  Comparisons of Dose-Volume Histograms for Proton-Beam versus 3-D Conformal X-Ray Therapy in Patients with Stage I Non-Small Cell Lung Cancer , 2009, Strahlentherapie und Onkologie.

[152]  K. Kubo,et al.  Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. , 2009, Japanese journal of clinical oncology.

[153]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[154]  Joe Y. Chang,et al.  Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[155]  H. Baloglu,et al.  The Effects of Tissue Fixation Alternatives on DNA Content: A Study on Normal Colon Tissue , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[156]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[157]  Simon Chapman,et al.  Impact of tobacco control policies and mass media campaigns on monthly adult smoking prevalence. , 2008, American journal of public health.

[158]  J. Aster,et al.  BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.

[159]  Yih-Leong Chang,et al.  Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. , 2007, The Journal of thoracic and cardiovascular surgery.

[160]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[161]  Joe Y. Chang,et al.  Stereotactic body radiation therapy for stage I non-small cell lung cancer. , 2007, Thoracic surgery clinics.

[162]  Joe Y. Chang,et al.  4D Proton treatment planning strategy for mobile lung tumors. , 2007, International journal of radiation oncology, biology, physics.

[163]  W. Travis,et al.  Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors. , 2007, Japanese journal of clinical oncology.

[164]  Radhe Mohan,et al.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[165]  Takehiko Fujisawa,et al.  Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis , 2006, Modern Pathology.

[166]  F. Cappuzzo,et al.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.

[167]  R Tibshirani,et al.  Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification , 2006, Oncogene.

[168]  S. Hirohashi,et al.  Array‐based comparative genomic hybridization analysis of high‐grade neuroendocrine tumors of the lung , 2005, Cancer science.

[169]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[170]  S. Senan,et al.  A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer. , 2004, Lung cancer.

[171]  Carl Virtanen,et al.  Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles , 2004, The Lancet.

[172]  J. Testa,et al.  Chromosomal imbalances in human lung cancer , 2002, Oncogene.

[173]  Y. Miyagi,et al.  Aberrant Nuclear Localization and Gene Mutation of β-catenin in Low-Grade Adenocarcinoma of Fetal Lung Type: Up-Regulation of the Wnt Signaling Pathway May Be a Common Denominator for the Development of Tumors that Form Morules , 2002, Modern Pathology.

[174]  Angela Greco,et al.  The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium , 2000, Oncogene.

[175]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[176]  A. Scharl,et al.  Expression of p16 and lack of pRB in primary small cell lung cancer , 1999, The Journal of pathology.

[177]  J M Slater,et al.  Proton-beam radiotherapy for early-stage lung cancer. , 1999, Chest.

[178]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[179]  David I. Smith,et al.  PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers , 1998, Oncogene.

[180]  J. Minna,et al.  Cigarettes, sex, and lung adenocarcinoma. , 1997, Journal of the National Cancer Institute.